IRIS
SANTANTONIO, TERESA ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.319
NA - Nord America 15.133
AS - Asia 12.297
SA - Sud America 2.376
Continente sconosciuto - Info sul continente non disponibili 1.375
AF - Africa 192
OC - Oceania 18
Totale 46.710
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.839
CN - Cina 4.781
IE - Irlanda 4.164
SG - Singapore 3.301
UA - Ucraina 3.174
BR - Brasile 1.964
RU - Federazione Russa 1.947
SE - Svezia 1.711
FR - Francia 1.371
HK - Hong Kong 1.241
IT - Italia 1.035
IN - India 974
VN - Vietnam 783
FI - Finlandia 719
TR - Turchia 699
DE - Germania 470
GB - Regno Unito 347
AR - Argentina 159
AT - Austria 147
BD - Bangladesh 107
MX - Messico 101
CA - Canada 100
EC - Ecuador 81
IQ - Iraq 75
EU - Europa 68
ID - Indonesia 63
ZA - Sudafrica 60
CO - Colombia 48
NL - Olanda 44
PK - Pakistan 40
JP - Giappone 38
ES - Italia 33
VE - Venezuela 32
CZ - Repubblica Ceca 31
BE - Belgio 30
SA - Arabia Saudita 29
CL - Cile 25
PL - Polonia 25
UZ - Uzbekistan 25
PY - Paraguay 24
TN - Tunisia 23
MA - Marocco 22
UY - Uruguay 22
EG - Egitto 20
KE - Kenya 20
DO - Repubblica Dominicana 16
DZ - Algeria 16
JM - Giamaica 16
NP - Nepal 15
AU - Australia 14
PE - Perù 14
TT - Trinidad e Tobago 14
AE - Emirati Arabi Uniti 13
IR - Iran 11
OM - Oman 11
KZ - Kazakistan 10
RO - Romania 10
SY - Repubblica araba siriana 10
TH - Thailandia 10
LT - Lituania 9
SV - El Salvador 9
AZ - Azerbaigian 8
BG - Bulgaria 8
CR - Costa Rica 8
JO - Giordania 8
PR - Porto Rico 8
HN - Honduras 7
PT - Portogallo 7
AL - Albania 6
BO - Bolivia 6
MY - Malesia 6
PA - Panama 6
RS - Serbia 6
SN - Senegal 6
CH - Svizzera 5
ET - Etiopia 5
LB - Libano 5
PS - Palestinian Territory 5
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
BH - Bahrain 3
BY - Bielorussia 3
GR - Grecia 3
IL - Israele 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
AO - Angola 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
KH - Cambogia 2
MK - Macedonia 2
Totale 45.377
Salva come PNG Salva come JPEG
Città #
Dublin 4.162
San Jose 2.598
Jacksonville 2.223
Singapore 1.388
Dearborn 1.306
Hong Kong 1.232
Chandler 1.218
Nanjing 1.160
Nyköping 877
Ashburn 791
Beijing 693
Wilmington 662
Santa Clara 546
Princeton 477
Nanchang 444
Lauterbourg 438
Dallas 426
San Mateo 370
Moscow 325
Shenzhen 301
Helsinki 280
Shenyang 258
Ho Chi Minh City 240
Ann Arbor 222
Tianjin 186
Kunming 178
Hebei 168
Hanoi 148
São Paulo 142
Jiaxing 140
Changsha 139
Hilden 133
Des Moines 128
Dong Ket 117
The Dalles 104
Vienna 104
New York 103
Los Angeles 101
Munich 97
Boardman 95
Hangzhou 95
Bari 90
Stevenage 88
Ningbo 79
Jinan 78
Nuremberg 73
Woodbridge 73
Rio de Janeiro 71
Guangzhou 66
Lanzhou 59
Zhengzhou 59
Foggia 54
Shanghai 51
Rome 47
Belo Horizonte 43
London 40
Changchun 37
Turku 36
Brasília 35
San Francisco 35
Taizhou 35
Tokyo 35
Campinas 34
Brooklyn 31
Guayaquil 31
Johannesburg 31
Mexico City 30
Milan 30
Orange 30
Frankfurt am Main 29
Haiphong 28
Orem 28
Boston 27
Philadelphia 27
Pune 27
Brussels 26
Chicago 26
Toronto 26
Atlanta 24
Da Nang 24
Guarulhos 24
Porto Alegre 24
Redwood City 24
Norwalk 23
Warsaw 23
Baghdad 22
Tashkent 22
Ankara 21
Curitiba 21
Salvador 21
Seattle 21
Auburn Hills 20
Borås 20
Chennai 20
Hefei 20
Dhaka 19
Phoenix 19
Wuhan 19
Biên Hòa 18
Brno 18
Totale 26.927
Salva come PNG Salva come JPEG
Nome #
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. 419
Diagnosi rapida di sepsi: emocoltura e multiplex real time PCR a confronto 417
Epatite cronica anti-HBe/HBV DNA positiva e mutanti pre-core del virus dell'epatite B 211
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 210
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 181
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 165
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 151
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 148
Mucormicosi rino-orbitaria: una patologia da tenere d'occhio 147
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study 147
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 146
TERAPIA DELL'EPATITE ACUTA B e C 143
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing 141
Clinical and virological features of Hepatitis B and Delta infections in anti-HIV carriers 140
Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. 138
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. 138
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 134
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 134
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 133
Chronic viral hepatitis in patients with beta-thalassaemia minor. 131
Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. 131
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 130
Natural course of acute hepatitis C: a long-term prospective study 129
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features 129
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 128
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 128
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 128
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic epatiti B 127
HCV infection is a risk factor for gallstone disease in liver cirrhosis: An Italian epidemiological survey 127
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 127
Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort 127
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 125
Clinical value of HIV p24 Ag in cerebrospinal fluid of symptomatic or asymptomatic HIV-infected patients 125
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant Chronic Hepatitis B 124
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 124
Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study 124
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 123
Flares during long-term entecavir therapy in chronic hepatitis B 123
Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2? 123
Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. 122
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 122
OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance. 121
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 121
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 120
Comparison between HCV RNA and E1/E2 antibodies in patients on IFN treatment 120
A proposito di epatite B. News da EASL 2008. 120
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 120
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. 120
Efficacy and Safety of Remdesivir over Two Waves of the Sars-CoV-2 Pandemic 120
Non-A,non-B hepatitis virus. 119
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. 119
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 119
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. 119
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 119
Tipizzazione fenotipica di Klebsiella Pneumoniae MDR mediante MALDI-TOFS MS in isolati clinici della Rianimazione A.O.U. OO. RR. Foggia 119
Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. 119
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. 118
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. 118
Lack of HBV and HDV replicative activity in HBsAg-positive intravenous drug addicts with immune deficiency due to HIV. 118
Diagnosi sierologica dell'epatite acuta da virus A. Messa a punto e valutazione di tre metodiche per la determinazione delle IgM specifiche anti-HAV 118
LE VARIANTI GENOMICHE DELLA REGIONE PRE-CORE DEL VIRUS DELL'EPATITE B: ASPETTI PATOGENETICI E CLINICI 118
Selection of a secretion incompetent mutant in the serum of a patient with severe hepatitis B 117
Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 116
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 116
Long-term response to interferon therapy in hepatitis B virus (HBV) pre-C mutants associated chronic hepatitis 116
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 116
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 116
Chronic hepatitis B: Advances in treatment. 116
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. 115
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. 115
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 115
Variation of pre-C and pre-S sequences during Interferon therapy 115
IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long-term Italian multicenter AISF study 115
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 115
Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. 114
Gly145 to Arg substitution in HBs antigen of liver transplant patients receiving polyclonal hepatitis B immune globulin 113
Lamivudine/Interferon combination therapy in anti-HBe positive chronic hepatitis B patients; a controlled pilot study. 112
Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. 112
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 112
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 112
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 112
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation 111
Determinazione immunoenzimatica delle IgA specifiche anti-HAV nella diagnosi sierologica dell'epatite A 111
RIELISA: a new principle for the simultaneous detection of total and IgM antibodies. Application to hepatitis diagnosis 111
Clinical and virological features of HBV and HDV chronic hepatitis in subjects with HIV infection 111
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 111
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues 110
Selection during interferon treatment for a pre-C stop codon mutation in a hepatitis B virus variant despite the simultaneous presence of a pre-C initiation codon mutation 110
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 110
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. 109
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 109
Rischio di Epatocarcinoma nei pazienti con Epatite Cronica B in trattamento con NUCs e soppressione virologica stabile 109
Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. 108
Dendritic Cell Maturation in HCV Infection: Altered Regulation of MHC Class I Antigen Processing-Presenting Machinery 108
A multicenter Italian study of rescue Adefovir Dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients 108
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients 108
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 108
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 108
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 108
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 108
Totale 12.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 242.387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.387
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.227 0 21 36 70 341 129 69 234 310 297 102 618
2022/20238.169 950 196 274 370 335 603 32 474 4.613 105 122 95
2023/20241.203 171 61 364 40 78 174 92 60 8 18 11 126
2024/20256.213 326 39 67 131 73 781 1.011 344 1.812 418 589 622
2025/202611.429 633 657 1.643 2.299 289 376 2.485 989 913 682 188 275
2026/2027185 184 1 0 0 0 0 0 0 0 0 0 0
Totale 46.710